Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, has been investigated in a mixed MDS/AML patient cohort of 165 patients in combination with the DNMTi decitabine.107. The gene discussed is BTK; the disease is acute myeloid leukemia.